Viemed Healthcare, Inc.
NASDAQ:VMDMedical - Devices
+$0.07 today
- Market cap
- $332.70M
- Beta
- 1.13
- P/E (TTM)
- 27.4
- EPS (TTM)
- $0.39
Volume 0.26M
Average 0.26M
VMD Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Viemed Healthcare, Inc.NASDAQ: VMD
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables growth accelerates
Q1 FY2026 accounts receivables of $5.59M (cash outflow) rose 197.8% year over year, ahead of the +32.8% change in trailing-twelve-month accounts receivables.
Context
- Accounts receivables amounted to 0.4% of revenue in FY2025, down 2.3 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +197.8% holds above the trailing-twelve-month pace of +32.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 1.16M USD
- Year-over-year change
- +119.1%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.16M | +119.1% |
| FY2024 | 2024-12-31 | (6.07M) | -463.7% |
| FY2023 | 2023-12-31 | (1.08M) | +91.4% |
| FY2022 | 2022-12-31 | (12.57M) | -71.1% |
| FY2021 | 2021-12-31 | (7.35M) | — |
Accounts Receivables vs competitors
How VMD compares with its peers on the latest reported figures
- VMD's LTM Mar 2026 accounts receivables of $2.56M is the 7th largest of the 11 companies compared; the peer median is $1.74M.
- Its year-over-year change of +32.8% is the 6th highest of 11, against a peer median of +44.2%.
- Accounts receivables amounts to 0.9% of revenue for VMD, versus a peer median of 5.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $11.95M | -5.6% | -34.3% | 3.4% | |
| LTM Mar 2026 | $11.43M | +537.2% | +141.9% | 28.1% | |
| LTM Mar 2026 | $9M | +948.6% | +27.2% | 6.2% | |
| LTM Mar 2026 | $8.65M | +7764.5% | — | 7.4% | |
| LTM Mar 2026 | $3.56M | -683.9% | -25.1% | 5.0% | |
| LTM Mar 2026 | $2.87M | -1376.9% | -66.6% | 5.0% | |
| LTM Mar 2026 | $2.56M | +32.8% | — | 0.9% | |
| LTM Mar 2026 | $2.34M | +94.0% | +9.5% | 5.3% | |
| LTM Mar 2026 | $1.14M | -118.2% | — | 1.4% | |
| LTM Dec 2025 | $113.84K | +135.5% | +13.1% | 0.9% | |
| LTM Mar 2026 | $92K | -82.2% | -22.0% | 0.2% | |
| Peer median (excluding VMD) | $1.74M | +44.2% | -6.2% | 5.0% | |
Competitors are the stored peer set for VMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 9.13M | 6.22M | 10.24M | 11.41M | 14.93M |
| Depreciation & Amortization | 11.31M | 15.63M | 21.86M | 25.37M | 28.61M |
| Deferred Income Tax | 3.88M | 1.75M | (1.44M) | (3.84M) | 3.11M |
| Stock-Based Compensation | 5.15M | 5.2M | 5.85M | 6.29M | 9.13M |
| Change in Working Capital | (13.56M) | (10.14M) | 7.78M | 355K | (2.3M) |
| Accounts Receivables | (7.35M) | (12.57M) | (1.08M) | (6.07M) | 1.16M |
| Inventory | (212K) | 301K | (480.66K) | 574K | 59K |
| Accounts Payables | 133K | (318K) | (874.75K) | 359K | 479K |
| Other Working Capital | (6.14M) | 2.45M | 10.21M | 5.5M | (4M) |
| Other Non-Cash Items | 6.58M | 9.08M | 921K | (488K) | (1.57M) |
| Operating Cash Flow | 22.49M | 27.75M | 45.21M | 39.09M | 51.92M |
| Capital Expenditures | (19.74M) | (22.9M) | (26.09M) | (37.77M) | (39.99M) |
| Acquisitions (Net) | (599K) | (141K) | (28.59M) | (3M) | (26.33M) |
| Purchases of Investments | (593.73K) | (2M) | 0 | 0 | 0 |
| Sales of Investments | 593.73K | 0 | 0 | 750K | 0 |
| Other Investing Activities | 596K | 1.06M | 2.57M | 9.32M | 16.15M |
| Investing Cash Flow | (19.75M) | (23.98M) | (52.11M) | (30.7M) | (50.17M) |
| Debt Repayment | (4M) | (5.84M) | 2.12M | (3.41M) | 8.15M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 1.44M |
| Common Stock Repurchased | (1.43M) | (9.71M) | (594K) | (1.07M) | (13.23M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 112K | 283K | 1.3M | 789K | (2.16M) |
| Financing Cash Flow | (5.32M) | (15.27M) | 2.83M | (3.69M) | (5.79M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (2.57M) | (11.49M) | (4.08M) | 4.7M | (4.04M) |
| Free Cash Flow | 2.75M | 4.85M | 19.12M | 1.32M | 11.93M |
Viemed Healthcare, Inc.
NASDAQ:VMD
Intrinsic Alpha fair value
Locked
Current Price
$8.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.